NovoCure (NVCR) Payables (2014 - 2026)

NovoCure (NVCR) has reported Payables for 13 consecutive years, with $130.7 million the latest figure, recorded in Q2 2026.

• Quarterly Payables fell 80.3% year-over-year to $130.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $130.7 million (down 80.3% YoY) and the FY2025 annual result came in at $122.2 million, down 81.57% from the prior year.
• Payables climbed to $130.7 million in Q2 2026 per NVCR's latest filing, from $127.2 million in the prior quarter.
• Over the last five years, Payables for NVCR reached as high as $679.5 million in Q3 2025 and fell as low as $69.2 million in Q1 2022.
• A 5-year average of $250.7 million and a median of $92.3 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables soared 714.19% — and 2025, when it tumbled 81.57%.
• Year by year, Payables stood at $85.2 million in 2022, then advanced by 10.79% to $94.4 million in 2023, then jumped by 602.66% to $663.2 million in 2024, then slumped by 81.57% to $122.2 million in 2025, then advanced by 6.95% to $130.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $130.7 million, $127.2 million, and $122.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.